Medtronic Board Approves Cash Dividend for Third Quarter of Fiscal 2025
On December 5, 2024, Medtronic plc (NYSE: MDT), a leading global healthcare technology company headquartered in Galway, Ireland, informed its shareholders of a significant development: the board of directors has approved a cash dividend for the third quarter of the fiscal year 2025, amounting to $0.70 per ordinary share. This announcement aligns with the previous dividend increase made in May 2024, reinforcing Medtronic's commitment to providing returns to its investors.
Medtronic has established a remarkable track record as a consistent dividend payer, featuring in the esteemed S&P 500 Dividend Aristocrats index. This accolade is a testament to the company's dedication to equity returns, showcasing its resilience and strategic management. The company has successfully raised its annual dividend for an impressive 47 consecutive years, a performance that speaks volumes about its operational stability and financial health.
The upcoming dividend will be payable on January 10, 2025, welcoming returns to shareholders who are on record by the close of business on December 27, 2024. This timing is significant as it reflects Medtronic's operational calendar and allows investors to partake in the company’s ongoing growth trajectory.
Medtronic’s mission is profound and transformative: to alleviate pain, restore health, and extend life. With a global team exceeding 95,000 employees spread across more than 150 countries, the company's innovative technologies and therapies address an extensive array of health conditions. These encompass critical areas such as cardiac devices, surgical robotics, insulin pumps, surgical tools, and patient monitoring systems.
According to Medtronic, two individuals experience life-changing outcomes through their technologies every second. This statistic encapsulates the core of their commitment: merging bold ideas with bolder actions to tackle some of the most pressing health challenges worldwide. Medtronic maintains a strong emphasis on uplifting patient care standards through an insight-driven approach, designed to prioritize people and yield better results.
Forward-looking statements from Medtronic are fortified by their robust operational framework and commitment to transparency with stakeholders. While they acknowledge risks and uncertainties in their business dynamics, the company continues to adapt and innovate, ensuring that they not only meet but exceed investor expectations.
For those interested in learning more about Medtronic and its endeavors in the healthcare space, details about their innovations and commitment to improving lives can be found on their official website at www.Medtronic.com. Follow them on LinkedIn for the latest updates, news, and insights that highlight the company's impactful initiatives.
In summary, Medtronic's declaration of a $0.70 cash dividend underscores its commitment to shareholder value and reflects the organization's enduring success in the healthcare technology sector. This news is not only important for investors but also signals Medtronic's ongoing contribution to improving healthcare outcomes worldwide.
Medtronic has established a remarkable track record as a consistent dividend payer, featuring in the esteemed S&P 500 Dividend Aristocrats index. This accolade is a testament to the company's dedication to equity returns, showcasing its resilience and strategic management. The company has successfully raised its annual dividend for an impressive 47 consecutive years, a performance that speaks volumes about its operational stability and financial health.
The upcoming dividend will be payable on January 10, 2025, welcoming returns to shareholders who are on record by the close of business on December 27, 2024. This timing is significant as it reflects Medtronic's operational calendar and allows investors to partake in the company’s ongoing growth trajectory.
Medtronic’s mission is profound and transformative: to alleviate pain, restore health, and extend life. With a global team exceeding 95,000 employees spread across more than 150 countries, the company's innovative technologies and therapies address an extensive array of health conditions. These encompass critical areas such as cardiac devices, surgical robotics, insulin pumps, surgical tools, and patient monitoring systems.
According to Medtronic, two individuals experience life-changing outcomes through their technologies every second. This statistic encapsulates the core of their commitment: merging bold ideas with bolder actions to tackle some of the most pressing health challenges worldwide. Medtronic maintains a strong emphasis on uplifting patient care standards through an insight-driven approach, designed to prioritize people and yield better results.
Forward-looking statements from Medtronic are fortified by their robust operational framework and commitment to transparency with stakeholders. While they acknowledge risks and uncertainties in their business dynamics, the company continues to adapt and innovate, ensuring that they not only meet but exceed investor expectations.
For those interested in learning more about Medtronic and its endeavors in the healthcare space, details about their innovations and commitment to improving lives can be found on their official website at www.Medtronic.com. Follow them on LinkedIn for the latest updates, news, and insights that highlight the company's impactful initiatives.
In summary, Medtronic's declaration of a $0.70 cash dividend underscores its commitment to shareholder value and reflects the organization's enduring success in the healthcare technology sector. This news is not only important for investors but also signals Medtronic's ongoing contribution to improving healthcare outcomes worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.